dc.creator | Rueda Domínguez, A. | es |
dc.creator | Alfaro Lizaso, J. | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Gumá i Padró, J. | es |
dc.creator | Quero Blanco, C. | es |
dc.creator | Gómez Codina, J. | es |
dc.creator | Llanos Muñoz, M. | es |
dc.creator | Martínez Banaclocha, N. | es |
dc.creator | Rodriguez Abreu, D. | es |
dc.creator | Provencio Pulla, M. | es |
dc.date.accessioned | 2024-04-03T14:24:14Z | |
dc.date.available | 2024-04-03T14:24:14Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Rueda Domínguez, A., Alfaro Lizaso, J., Cruz Merino, L.d.l., Gumá i Padró, J., Quero Blanco, C., Gómez Codina, J.,...,Provencio Pulla, M. (2015). SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clinical and Translational Oncology, 17 (12), 100507-1013. https://doi.org/10.1007/s12094-015-1429-1. | |
dc.identifier.issn | 1699-048X | es |
dc.identifier.issn | 1699-3055 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156647 | |
dc.description.abstract | Hodgkin lymphoma (HL) is an uncommon B
cell lymphoid malignancy representing approximately
10–15 % of all lymphomas. HL is composed of two dis tinct disease entities; the more commonly diagnosed clas sical HL and the rare nodular lymphocyte-predominant HL.
An accurate assessment of the stage of disease and prog nostic factors that identify patients at low or high risk for
recurrence are used to optimize therapy. Patients with early
stage disease are treated with combined modality strategies
using abbreviated courses of combination chemotherapy
followed by involved-field radiation therapy, while those
with advanced stage disease receive a longer course of
chemotherapy often without radiation therapy. High-dose
chemotherapy (HDCT) followed by an autologous stem
cell transplant (ASCT) is the standard of care for most
patients who relapse following initial therapy. Brentuximab
vedotin should be considered for patients who fail HDCT
with ASCT. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.relation.ispartof | Clinical and Translational Oncology, 17 (12), 100507-1013. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Oncohematology malignancies | es |
dc.subject | Hodgkin lymphoma | es |
dc.subject | Hodgkin lymphoma therapy | es |
dc.title | SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s12094-015-1429-1 | es |
dc.identifier.doi | 10.1007/s12094-015-1429-1 | es |
dc.contributor.group | Universidad de Sevilla. CTS151: Bioquímica médica. | es |
dc.journaltitle | Clinical and Translational Oncology | es |
dc.publication.volumen | 17 | es |
dc.publication.issue | 12 | es |
dc.publication.initialPage | 100507 | es |
dc.publication.endPage | 1013 | es |